View:
United States securities and exchange commission logo
September 2, 2021
Samuel Reich
Chief Executive Officer
Big Cypress Acquisition Corp.
300 W. 41st Street, Suite 202
Miami Beach, FL 33140
Re: Big Cypress
Acquisition Corp.
Registration
Statement on Form S-4
Filed August 17,
2021
File No. 333-258869
Dear Mr. Reich:
We have reviewed your registration statement and have the
following comments. In
some of our comments, we may ask you to provide us with information so
we may better
understand your disclosure.
Please respond to this letter by amending your registration
statement and providing the
requested information. If you do not believe our comments apply to your
facts and
circumstances or do not believe an amendment is appropriate, please tell
us why in your
response.
After reviewing any amendment to your registration statement and
the information you
provide in response to these comments, we may have additional comments.
Form S-4 Filed August 17, 2021
SAB Biotherapeutics operates in a highly competitive industry, page 46
1. We note your response
to prior comment 12. Please expand your disclosure further to
identify the specific
products and technologies that you have identified as competitors of
your current product
pipeline.
Research and Development, Pipeline Programs, page 123
2. We note your response
to prior comment number 25. Please remove the progress bars
from the Indication
column so that they only show the progress in preclinical and clinical
development.
Samuel Reich
FirstName
Big CypressLastNameSamuel Reich
Acquisition Corp.
Comapany 2,
September NameBig
2021 Cypress Acquisition Corp.
September
Page 2 2, 2021 Page 2
FirstName LastName
Regulatory Matters, page 125
3. We note your response to prior comment 32. Please revise your
disclosure on page 127 to
clarify which product candidate (or candidates, as applicable) is
currently in Phase 2a trial
in the U.K. and which is regulated by the MHRA.
Intellectual Property, page 131
4. We note that the patents granted under Patent Family A, which expired
in March 2021 and
February 2021. Please discuss the impact on your business of the
expiry of such patents.
Please also revise the table on page 131 to clarify the patent
protection for each Patent
Family and to specify the patent protection in the abstracts for
Patent Families D, H, K
and L.
SAB MD&A
Liquidity and Capital Resources, page 139
5. Please refer to prior comment 35. We do not see where you revised your
disclosure
regarding your outstanding receivables. Explain to us where you have
disclosed this
information or revise your disclosures accordingly.
SAB Biotherapeutics, Inc. Consolidated Financial Statements
Note 2 - Summary of Significant Accounting Policies
Research and development expenses, page F-52
6. Please refer to prior comment 37. We do not see where you expanded
your CRO
contracts. Explain to us where you have disclosed this information or
revise your
disclosures accordingly.
We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
Samuel Reich
Big Cypress Acquisition Corp.
September 2, 2021
Page 3
You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Jane Park at 202-551-7439 or Christopher Edwards at 202-551-6761 with any other
questions.
Sincerely,
FirstName LastNameSamuel Reich
Division of
Corporation Finance
Comapany NameBig Cypress Acquisition Corp.
Office of Life
Sciences
September 2, 2021 Page 3
cc: Ilan Katz, Esq.
FirstName LastName